..далее (8.1-9.4)

8.1. Головная боль, связанная с острым или длительным воздействием веществ

    Altura BM, Altura BT, Gebrewold A. Alcohol induced spasm of cerebral blood vessels. J Mental Sci 2000; 104:972-99.

    Armstrong PJ, Bersten A. Normeperidine toxicity. Anesth Analg 1986; 65:536-8.

    Ashina M, Bendtsen L, Jensen R, Olesen J. Nitric oxide-induced headache in patients with chronic tension-type headache. Brain 2000; 123:1830-7.

    Askew GL, Finelli L, Genese CA, Sorhage FE, Sosin DM, Spi-talny KC. Bouillabaisse: an outbreak of methemoglobinemia in New Jersey in 1992. Pediatrics 1994; 94:381-4.

    Askmark H, Lundberg PO, Olsson S. Drug related headache. Headache 1989; 29:441-4.

    Atkins FM. A critical evaluation of clinical trials in adverse reactions to foods in adults. J Allergy Clin Immunol 1986; 78:174-82.

    Beck HG, Schulze WH, Suter GM. Carbon monoxide — a domestic hazard. JAMA 1940; 115:1.

    Bonnet GF, Nepveux P. Migraine due to tyramine. Sem Hop 1971; 47:2441-5.

    Brewerton TD, Murphy DL, Lesem MD, Brandt HA, Jimerson DC. Headache responses following mchlorophenylpiperazine in bulimics and controls. Headache 1992; 32:217-22.

    Catalano G, Catalano MC, Rodriguez R. Dystonia associated with crack cocaine use. South Med J 1997; 90:1050-2.

    Cleophas TJ, Niemeyer MG, vanderWall EE, vanderMe, uJen J. Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dose. Angiology 1996; 47:679-85.

    Council of Scientific Affairs. Aspartame: review of safety issues. JAMA 1985; 254:400-2.

    Cregler LL, Mark H. Medical complications of cocaine abuse. N Engl J Med 1986; 315:1495-501.

    Dhopesh V, Maany I, Herring C. The relationship of cocaine to headache in polysubstance abusers. Headache 1991; 31:17-9.

    Dhuna A, Pascual-Leone A, Belgrade M. Cocaine-related vascular headaches. J Neurol Neurosurg Psychiat 1991;54:803-6.

    De Marinis M, Janiri L, Agnoli A. Headache in the use and withdrawal of opiates and other associated substances of abuse. Headache 1991; 31:159-63.

    Ekbom K. Nitroglycerin as a provocative agent in cluster headache. Arch Neurol 1968; 19:487-93.

    el-Mallakh RS. Marijuana and migraine. Headache 1987; 27:442-3.

    el-Mallakh RS, Kranzler HR, Kamanitz JR. Headaches and psychoactive substance use. Headache 1991; 31:584-7.

    Forbes HS, Cobb S, Fremont-smith F. Cerebral edema and headache following carbon monoxide asphyxia. Arch Neurol Psychiatr 1924; 11:164.

    Gawin FH. Cocaine addiction: psychology and neurophysiology. Science 1991; 251:1580-6.

    Ghose K, Carrol JD. Mechanisms of tyramine-induced migraine: similarities with dopamine and interactions with disulfiram and propranolol. Neuropsychiobiol 1984; 12:122-6.

    Gordon CR, Mankuta D, Shupak A, Spitzer O, Doweck I. Recurrent classic migraine attacks following transdcrmal scopolamine intoxication. Headache 1991; 31:172-1.

    Gore ME, Salmon PR. Chinese restaurant syndrome: fact or fiction. Lancet 1980; 318:251-2.

    Hanington E, Harper AM. The role of tyramine in the etiology of migraine and related studies on the cerebral and intracerebral circulations. Headache 1968; 8:84-97.

    Hansen HJ, Drewes VM. The nitroglycerine ointment test — a double-blind examination. Dan Med Bull 1970; 7:226-9.

    Heckerling PS, Leikin JB, Maturen A, Perkins JT. Predictors of occult carbon monoxide poisoning in patients with headache and dizziness. Ann Int Med 1987; 107:174-6.

    Henderson WR, Raskin NH. ’Hot dog’ headache: individual susceptibility to nitrite. Lancet 1972; ii:1162-3.

    Hirsch AR, Rankin KM, Panelli PP. Trichloroethylene exposure and headache. Headache Quarterly 1996; 7:126-38.

    Horowitz LD, Herman MV, Gorlin R. Clinical response to nitroglycerine as a diagnostic test for coronary artery disease. Am J Cardiol 1972; 29:149-53.

    Iversen HK, Nielsen TM, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989; 38:17-24.

    Kenney RA, Tidball CS. Human susceptibility to oral monosodium 1-glutamate. Am J Clin Nutr 1972; 25:140-6.

    Kerr GR, Lee MW, elLozy M, McGandy R, Stare F. Prevalence of the ’Chinese restaurant syndrome’. J Am Diet Assoc 1979; 75:29-33.

    Krabbe AA, Olesen J. Headache provocation by continuous intravenous infusion of histamine, clinical results and receptor mechanisms. Pain 1980; 8:253-9.

    Larkin JM, Brahos GJ, Moylin JA. Treatment of carbon monoxide poisoning: prognostic factors. J Trauma 1976; 16:111.

    Lassen LH, Thomsen LL, Olesen J. Histamine induces migraine via the H receptor. Support for the NO-hypothesis of migraine. Neuroreport 1995; 6:1475-9.

    Leon AS, Hunninghake DB, Bell C, Rassin DK, Tephly TR. Safety of long-term doses of aspartame. Arch Int Med 1989; 149:2318-24.

    Leone M, Attanasio A, Croci D, Filippini G, D’Amico D, Grazzi L, Nespolo A, Bussone G. The serotonergic agent m-chlorophenylpiperazine induced migraine attacks: a controlled study. Neurology 2000; 55:136-9.

    Levine SR, Brust JC, Futrell N, et al. Cerebrovascular complications of the use of the crack form of alkaloidal cocaine. N Engl J Med 1990; 323:699-704.

    Lipton RB, Kwong CM, Solomon S. Headaches in hospitalized cocaine users. Headache 1989; 29:225-8.

    Lowenstein DH, Massa SM, Rowbotham MC et al. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med 1987; 83:841-6.

    Luthy J, Schlatter C. Biogenic amines in food: effects of histamine, tyramine and phenylethylamine in the human. Z Lebensm Unters Forsch 1983; 177:439-43.

    McCullock J, Harper AM. Phenylethylamine and the cerebral circulation. In Current concepts in migraine research (McCullock J, Harper AM, eds.). Raven Press, New York. 1978, pp. 85-8.

    Meigs JL, Hughes JP. Acute carbon monoxide poisoning: an analysis of 105 cases. AMA Arch Ind Hygiene Occupat Med 1952; 6:344-56.

    Merkel PA, Koroshetz WJ, Irizarry MC, Cudkovicz ME. Cocaine-associated cerebral vasculitis. Semin Arthritis Rheum 1995; 25:172-83.

    Merrit JE, Williams PB. Vasospasm contributes to monosodium glutamate-induced headache. Headache 1990; 30:575-80.

    Mitchell JD. Clinical neurotoxicology: an introduction. In Handbook of Clinical Neurology (DeWolff FA, ed.). Elsevier Science, 1995, pp. 1-22.

    Moffet AM, Swash M, Scott DP. Effect of chocolate in migraine: a double-blind study. J Neurol Neurosurg Psychiatry 1974; 37:445-8.

    Monteiro JM. Headache associated with single use of substances. In The headaches (Olesen J, Tfelt-Hansen P, Welch KMA, eds.). Raven Press, Limited, New York. 1993, pp. 715-20.

    Monteiro JM, Dahlof CG. Single use of substances. In The Headaches (Olesen J, Tfelt-Hansen P, Welch KM, eds.). Lip-pincott Williams & Wilkins, Philadelphia. 2000, pp. 861-9.

    Murphree AB, Greenberg LA, Carrol RB. Neuropharmaco-logic effects of substances other than ethanol in alcoholic beverages. Fed Proc 1967; 26:1468-73.

    Norton S. Toxicology of the central nervous system. In Toxicology (Casarett LJ, Doult J, eds.). MacMillan, New York. 1975, pp. 1019-35.

    Ogata S, Hosoi T, Saji H. Studies on acute alcohol intoxication. Japanese Journal of Studies of Alcohol 1966; 1:67-79.

    Peters GA. Migraine: diagnosis and treatment with emphasis on the migraine-tension headache, provocative tests and use of rectal suppositories. Proc Mayo Clin 1953; 28:673-86.

    Reif-Lehrer L. A questionnaire study of the prevalence of Chinese restaurant syndrome. Fed Proc 1977; 36:1617-23.

    Sabatini U, Rascol O, Rascol A, Montastruc JL. Migraine attacks induced by subcutaneous apomorphine in two migrainous Parkinson Ian patients. Clin Neuropharmacol 1990; 13:264-7.

    Satel SL, Gawin FH. Migraine-like headache and cocaine use. JAMA 1989; 261:2995-6.

    Schamburg HH, Byck R, Gerstl R, Mashman JH. Monosodium L-glutamate: its pharmacology and role in the Chinese restaurant syndrome. Science 1969; 163:826-8.

    Scher W, Scher BM. A possible role for nitric oxide in gluta-mate (MSG)-induced Chinese restaurant syndrome, gluta-mate induced asthma, ’hot-dog headache’, pugilistic Alzheimer’s disease, and other disorders. Med Hypotheses 1992; 38:185-8.

    Schiffmann SS, Buckley CE, Sampson HA et al. Aspartame and susceptibility to headache. N Engl J Med 1987; 317:1181-5.

    Schnitker MT, Schnitker MA. Clinical notes, suggestions and new instruments. JAMA 1947; 135:89.

    Schwartz AM. The cause, relief and prevention of headache arising from contact with dynamite. N Engl J Med 1946; 235:541-4.

    Scopp AL. MSG and hydrolyzed vegetable protein induced headache review and case studies. Headache 1991; 31:107-10.

    Seltzer S. Foods and drug combinations, responsible for head and neck pain. Cephalalgia 1982; 2:111-24.

    Shaw SW, Johnson RH, Keogh HG. Oral tyramine in dietary migraine sufferers. In Current concepts in migraine research (Shaw SW, Johnson RH, Keogh HG, eds.). Raven Press, New York. 1978, pp. 31-9.

    Shively M, Riegel B. Effect of nitroglycerin ointment placement on headache and flushing in health subjects. Int J Nurs Stud 1991; 28:153-61.

    Sicuteri F, Bene ED, Poggioni M, Bonazzi A. Unmasking latent dysnociception in healthy subjects. Headache 1987; 27:180-5.

    Smith I, Kellow AH, Hanington E. Clinical and biochemical correlation between tyramine and migraine headache. Headache 1970; 10:43-52.

    Tarasoff L, Kelly ME Monosodium L-glutamate: a double-blind study and review. Food Chem Toxicol 1993; 31:1019-35.

    Thomsen LL, Kruse C, Iversen HK, Olesen J. A Nitric oxide donor triggers genuine migraine attacks. Eur J Neurol 1994; 1:71-80.

    Towers CV, Pircon RA, Nageotte MP, Porto M, Garite TJ. Cocaine intoxication presenting as preeclampsia and eclampsia. Ob Gyn 1993; 81:545-7.

    Trelles L, Jeri R. Central nervous system stimulants: cocaine, amphetamine, nicotine. In Handbook of clinical neurology (DeWolff FA, ed.). New York: Elsevier Science, 1995, pp. 251-7.

    Wallgreen H, Barry A. Drug actions in relation to alcohol effects. In: Action of alcohol. New York: Elsevier, 1970, pp. 621-714.

    Wilson J. Cyanogenic glycosides. Ch. 3 in Handbook of clinical neurology, vol. 65 (DeWolff FA, ed.). New York: Elsevier Science, 1995, pp. 25-34.

    Varon J, Marik PE, Fromm RE, Gueler A. Carbon Monoxide Poisoning: a review for clinicians. J Emerg Med 1999; 17:87-93.

    Yang WH, Drouin MA, Herbert M, Mao Y, Kursh J. The monosodium glutamate symptom complex: assessment in a double blind, placebo controlled, randomized study. J Allergy Clin Immunol 1997; 99:757-62.

8.2. Головная боль при избыточном применении лекарственных препаратов (абузусная головная боль)

    Ala-Hurula V, Myllyla V, Hokkanen E. Ergotamine abuse: results of ergotamine discontinuation with special reference to the plasma concentrations. Cephalalgia 1982; 2:189-95.

    Ala-Hurula V, Myllyla V, Hokkanen E, Tokola O. Tolfenamic acid and ergotamine abuse. Headache 1981; 21:240-2.

    Allgulander C. History and current status of sedative-hypnotic drug use and abuse. Acta Psychiatr Scand 1986; 73:465-78.

    Andersson PG. Ergotamine headache. Headache 1975; 15:118-21.

    Baar HA. Treatment for headache: a four-step standardized withdrawal program for analgesic abusers. Pain Clin 1990; 3:173-7 (Abstract).

    Bennett WM, DeBroe ME. Analgesic nephropathy: a preventable renal disease. N Eng J Med 1989; 320:1269-71.

    Bowdler I, Killian J, Gansslen-Blumberg S. The association between analgesic abuse and headache — coincidental or causal. Headache 1988; 28:494.

    Braithwaite RA. The toxicity of tricyclic and newer antide-pressants. In Handbook of Clinical Neurology (DeWolff FA, ed.). New York: Elsevier Science, 1995, pp. 311-20.

    Brust JC. Opiate addiction and toxicity. Ch. 16 in Handbook of clinical neurology, vol. 65 (DeWolff FA, ed.). New York: Elsevier Science, 1995, pp. 356-61.

    Catarci T, Fiacco F, Argentine C. Ergotamine-induced headache can be sustained by sumatriptan daily intake. Cephalalgia 1994; 14:374-5.

    Centonze V, Polite BM, diBari M, Caporaletti P, Albano O. Vascular injuries in ergotamine abuse: a case report. Funct Ncurol 1993; 8:265-70.

    Dalquen P, Fasel J, Mihatsch MJ, Rist M, Rutishauser G. Phenacetinabusus IV. Sind zytologische harnuntersuchun-gen in der tumorvorsorge bei phenacetinabusern erfolgver-sprechend und anwendbar. Schweizerische Medizinische Wochenschrift 1980; 110:302-6.

    DeBroe ME, Elseviers MM. Analgesic nephropathy — still a problem? Nephron 1993; 64:505-13.

    deMarinis M, Janiri L, Agnoli A. Headache in the use and withdrawal of opiates and other associated substances of abuse. Headache 1991; 31:159-63.

    Diamond S, Dalessio DJ. Drug abuse in headache. In The practicing physician’s approach to headache (Diamond S, Dalessio DJ, eds.). Williams & Wilkins, Baltimore. 1982, pp. 114-21.

    Dichgans J, Diener HC. Clinical manifestations of excessive use of analgesic medication. In Drug — induced headache (Diener HC, Wilkinson M, eds.). Springer-Verlag, Berlin. 1988, pp. 8-15.

    Dichgans J, Diener HD, Gerber WD et al. Analgetika — induzierter dauerkopfschmerz. Dtsch Med Wschr 1984, 109:369-73.

    Diener HC. A personal view of the classification and definition of drug dependence headache. Cephalalgia 1993; 13:68-71.

    Diener HC, Dahlof CG. Headache associated with chronic use of substances. In The headaches (Olesen J, Tfelt-Hansen P, Welch KMA, eds.). Lippincott, Williams & Wilkins, Philadelphia. 1999, pp. 871-8.

    Diener HC, Dichgans J, Scholz E, Geiselhart S, Gerber WD, Bille A. Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989; 236:9-14.

    Diener HC, Haab J, Peters C, Ried S, Dichgans J, Pilgrim A. Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. Headache 1991; 31:205-9.

    Diener HC, Pfaffenrath V, Soyka D, Gerber WD. Therapie des medikamenten-induzierten dauerkopfschmerzes. Munch Med Wschr 1992; 134:159-62.

    Diener HC, Tfelt-Hansen P. Headache associated with chronic use of substances. In The headaches (Olesen J, Tfelt-Hansen P, Welch KMA, eds.). Raven press LTD, New York. 1993, pp. 721-7.

    Dige-Petersen H, Lassen NA, Noer J, Toennesen KH, Olesen J. Subclinical ergotism. Lancet 1977; 11:65-6.

    Drucker P, Tepper S. Daily sumatriptan for detoxification from rebound. Headache 1998; 38:687-90.

    Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med 1983; 308:357-62.

    Elkind AH. Drug abuse in headache patients. Clin J Pain 1989; 5:111-20.

    Elkind AH. Drug abuse and headache. Med Clin N Am 1991; 75:717-32.

    Evers S, Gralow I, Bauer B, Suhr B, Buchheister A, Husstedt IW, Ringelstein EB. Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin Neuropharmacol 1999; 22:201-6.

    Fanciullaci M, Alessandri M, Pietrini U, Briccolani-Bandini E, Beatrice S. Long-term ergotamine abuse: effect on adrener-gically induced mydriasis. Clin Pharm Ther 1992; 51:302-7.

    Fincham JE. Over-the-counter drug use and misuse by the ambulatory elderly: a review of the literature. J Ger Drug Ther 1987; 1:3-21.

    Fincham RW, Perdue Z, Dunn VD. Bilateral focal cortical atrophy and chronic ergotamine abuse. Neurology 1985; 35:720-2.

    Fisher CM. Analgesic rebound headache refuted. Headache 1988; 28:666.

    Friedman AP, Brazil P, vonStorch TJ. Ergotamine tolerance in patients with migraine. JAMA 1955; 157:881-4.

    Gaist D, Hallas J, Sindrup SH, Gram LF. Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 1996; 50:161-5.

    Gaist D, Tsiropoulus I, Sindrup SH, Hallas J, Rasmussen BK, Kragstrup J. Inappropriate use of sumatriptan: population based register and interview study. Br J Med 1998; 316:1352-3.

    Granella F, Farina S, Malferrari G, Manzoni GC. Drug abuse in chronic headache: a clinicoepidemiologic study. Cephalalgia 1987; 7:15-9.

    Gutzwiller F, Zemp E. Der analgetikakonsum in der bevolkerung und sociookonomische aspekte des anal-getikaabusus. In Das analgetikasyndrom (Mihatsch MJ, ed.). Thieme, Stuttgart. 1986, pp. 197-205.

    Hering R, Steiner TJ. Abrupt outpatient withdrawal from medication in analgesic-abusing migraineurs. Lancet 1991; 337:1442-3.

    Hokkanen E, Waltimo O, Kallanranta T. Toxic effects of ergotamine used for migraine. Headache 1978; 18:95-8.

    Horowski R, Ziegler A. Possible pharmacological mechanisms of chronic abuse of analgesics and other antimigraine drugs. In Drug-induced headache (Diener HC, Wilkinson M, eds.). Springer-Verlag, Berlin. 1988, pp. 95-104.

    Horton BT, Peters GA. Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: report of 52 cases. Headache 1963; 3:214-26.

    Isler H. Migraine treatment as a cause of chronic migraine. In Advances in migraine research and therapy (Rose FC, ed.). Raven Press, New York. 1982, pp. 159-64.

    Jaffe JH. Drug addiction and drug abuse. In The pharmacological basis of therapeutics (Gilman AG, Rail TW, Nies AS, Taylor P, eds.). Pergamon Press, New York. 1985, pp. 522-73.

    Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57:1694-8.

    Kaube H, May A, Diener HC, Pfaffenrath V. Sumatriptan misuse in daily chronic headache. Br Med J 1994; 308:1573.

    Kielholz P, Ladewig D. Probleme des medikamentenmi beta-brauches. Schweiz Arztezeitung 1981; 62:2866-9.

    Klapper JA. Rebound headache: definition, symptomatology, treatment, and prevention. Headache Quarterly 1992; 3:398-02.

    Kouyanou K, Pither CE, Rabe-Hesketh S, Wessely S. A comparative study of iatrogenesis, medication abuse, and psychiatric morbidity in chronic pain patients with and without medically explained symptoms. Pain 1998; 76:417-26.

    Kudrow L. Paradoxical effects of frequent analgesic use. Adv Neurol 1982; 33:335-41.

    Lader M. Hypnotics and sedatives. In Handbook of clinical neurology (DeWolff FA, ed.). New York: Elsevier Science, 1995, pp. 329-55.

    Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headache de novo? Headache 1988; 28:61-2.

    Lance JW. A concept of migraine and the search for the ideal headache drug. Headache 1990; 30:17-23.

    Limmroth V, Kazarawa S, Fritsche G, Diener HC. Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan. Lancet 1999; 353:378.

    Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59:1011-14.

    Lucas RN, Falkowski W. Ergotamine and methysergide abuse in patients with migraine. Br J Psychiatry 1973; 122:199-203.

    Ludolph AC, Husstedt IW, Schlake HP, Grotemeyer KH, Brune GC. Chronic ergotamine abuse: evidence of functional impairment of long ascending spinal tracts. Eur Neurol 1988; 28:311-6.

    MacGregor EA, Vorah C, Wilkinson M. Analgesic use: a study of treatments used by patients for migraine prior to attending the City of London migraine clinic. Headache 1990; 30:634-8.

    Manzoni GC, Micieli G, Granella F, Sandrini G, Zanferrari C, Nappi G. Therapeutic approach to drug abuse in headache patients. In Drug-induced headache (Diener HC, Wilkinson M, eds.). Springer-Verlag, Berlin. 1988, pp. 143-9.

    Marks V. Reactive (rebound) hypoglycemia. In Hypoglycemia (Marks V, Rose CF, eds.). Blackwell, Oxford. 1981, pp. 179-217.

    Mathew NT. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache 1987; 27:130-3.

    Mathew NT, Kurman R, Perez F. Drug induced refractory headache — clinical features and management. Headache 1990; 30:634-8.

    Michultka DM, Blanchard EB, Appelbaum KA, Jaccard J, Dentinger MP. The refractory headache patient-2. High medication consumption (analgesic rebound) headache. Behav Res Ther 1989; 27:411-20.

    Micieli G, Manzoni GC, Granella F, Martignoni E, Malferrari G, Nappi G. Clinical and epidemiological observations on drug abuse in headache patients. In Drug-Induced Headache (Diener HC, Wilkinson M, eds.). Springer-Verlag, Berlin. 1988, pp. 20-8.

    Nicolodi M, DelBianco PL, Sicuteri F. The way to serotoner-gic use and abuse in migraine. Int J Clin Pharmacol Res 1997; 17:79-84.

    Page H. Rebound headache from ergotamine withdrawal. JAMA 1981; 246:719.

    Peters G, Horton BT. Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proc Mayo Clin 1951; 26:153-61.

    Pini LA, Trenti T. Case report: does chronic use of sumatrip- tan induce dependence? Headache 1994; 34:600-1.

    Pradalier A, Dry S, Baron JF. Cephalee induite par 1’abuse de tartrate d’ergotamine chez les migrainieux. Concours Med 1984; 106:106-10.

    Rahman A, Segasothy M, Samad SA, Zulfiqar A, Rani M. Analgesic use and chronic renal disease in patients with headache. Headache 1993; 33:442-5.

    Rapoport A, Stang P, Gutterman DL, Cady R, Markley H, Weeks R, Saiers J, Fox AW. Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996; 36:14-9.

    Rapoport AM. Analgesic rebound headache. Headache 1988; 28:662-5.

    Rapoport AM, Weeks RE. Characteristics and treatment of analgesic rebound headache. In Druginduced headache (Diener HC, Wilkinson M, eds.). Springer-Verlag, Berlin. 1988, pp. 162-7.

    Roswell AR, Neylan C, Wilkinson M. Ergotamine induced headache in migrainous patients. Headache 1973; 13:65-7.

    Sandier DP, Smith JC, Weinberg CR, Buckalew VM, Dennis VW, Blythe WB, Burgess WP. Analgesic use and chronic renal disease. N Engl J Med 1989; 320:1238-43.

    Saper JR. Drug abuse among headache patients. In Headache disorders (Saper JR, ed.). PSG Publishers, Boston. 1983, pp. 263-78.

    Saper JR. Drug overuse among patients with headache. Neurol Clin 1983; 1:465-77.

    Saper JR. Daily chronic headaches. Neurol Clin N Amer 1990; 8:891-902.

    Saper JR, Jones JM. Ergotamine tartrate dependency: features and possible mechanisms. Clin Neuropharmacol 1986; 9:244-56.

    Schnider P, Aull S, Baumgartner C et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five-year followup. Cephalalgia 1996; 16:481-5.

    Schnider P, Aull S, Feucht M. Use and abuse of analgesics in tension-type headache. Cephalalgia 1994; 14:162-7.

    Schnider P, Maly J, Grunberger J, Aull S, Zeiler K, Wessely P. Improvement of decreased critical flicker frequency in headache patients with drug abuse after successful withdrawal. Headache 1995; 35:269-72.

    Schoenen J, Lenarduzzi P, Sianard-Gainko J. Chronic headaches associated with analgesics and/or ergotamine abuse: a clinical survey of 434 consecutive outpatients. In New advances in headache research (Rose FD, ed.). Smith-Gordon, London. 1989, pp. 29-43.

    Seller EM, Busto UE, Kaplan HL, Somer G, Baylon GJ. Comparative abuse liability of codeine and naratriptan. Clin Pharmacol Ther 1998; 63:121.

    Shakir RA. Vitamin toxicity. In Handbook of clinical neurology, vol. 65 (DeWolff FA, ed.). New York: Elsevier Science, 1995, pp. 567-76.

    Silberstein SD, Lipton RB. Chronic daily headache. In Headache (Goadsby PJ, Silberstein SD, eds.). Butterworth-Heinemann, Newton. 1997, pp. 201-25.

    Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classifiation of daily and near daily headaches: proposed revisions to the 1HS classification. Headache 1994; 34:1-7.

    Silberstein SD, Silberstein JR. Chronic daily headache: prognosis following inpatient treatment with repetitive IV DHE. Headache 1992; 32:439-45.

    Stewart JH. Analgesic abuse and renal failure in Australia. Kidney International 1978; 13:72-8.

    Sullivan JT, Sellers EM. Treatment of the barbiturate abstinence syndrome. Med J Aust 1986; 145:456-8.

    Taschner KL, Wiesbeck GA. Psychiatric aspects of drug addiction of the barbiturate-alcohol type. In Drug-induced headache (Diener HC, Wilkinson M, eds.). Berlin, Springer-Verlag. 1988, pp. 80-4.

    Tfelt-Hansen P. Ergotamine headache. In Updating in headache (Pfaffenrath V, Lundberg P, Sjaastad O, eds.). Springer, Berlin. 1985, pp. 169-72.

    Tfelt-Hansen P. The effect of ergotamine on the arterial system in man. Acta Pharmacol Toxicol 1986; 59:1-29.

    Tfelt-Hansen P, Krabbe AA. Ergotamine. Do patients benefit from withdrawal? Cephalalgia 1981; 1:29-32.

    Tfelt-Hansen P, Olesen J. Arterial response to ergotamine tar-trate in abusing and non-abusing migraine patients. Acta Physiol Scand 1981; 48:69-72.

    Tfelt-Hansen P, Paalzow L. Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther 1985; 37:29-35.

    Tfelt-Hansen P, Saxena PR, Ferrari MD. Ergot alkaloids. In Handbook of clinical neurology (DeWolff FA, ed.). New York: Elsevier Science. 1995, pp. 61-7.

    Timmings PL, Richens A. Neurotoxicology of antiepileptic drugs. In Handbook of clinical neurology (DeWolff FA, ed.). New York: Elsevier Science. 1995, pp. 495-513.

    Vasconcellos E, Pina-Garza JE, Millan EJ, Warner JS. Analgesic rebound headache in children and adolescents. J Child Neurol 1998; 13:443-7.

    Verhoeff NP, Visser WH, Ferrari MD, Saxena PR, vonRoen EA. Dopamine D2 receptor imaging with 123-I-iodobenza-mide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier. Cephalalgia 1993; 13:325-9.

    VonKorff M, Galer BS, Stang P. Chronic use of symptomatic headache medications. Pain 1995; 62:179-86.

    Walker J, Parisi S, Olive D. Analgesic rebound headache: experience in a community hospital. Southern Med J 1993; 86:1202-5.

    Warner JS. Rebound headaches: a review. Headache Quarterly 1999; 10:207-19.

    Zed PJ, Loewen PS, Robinson G. Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother 1999; 33:61-72.

    Ziegler DK. Opiate and opioid use in patients with refractory headache. Cephalalgia 2000; 14:5-10.

8.3. Головная боль как побочный эффект длительного приема лекарственных препаратов

    Dalton K. Migraine and oral contraceptives. Headache 1976; 15:247-51.

    de Lignieres B, Silberstein SD. Pharmacodynamics of oestro-gens and progestagens. Cephalalgia 2000; 20:200-7.

    Magos AL, Brewster E, Singh R, O’Dowd T, Brincat M, Studd JWW. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 1986; 93:1290-6.

    Nappi RE, Cagnacci A, Granella F, Piccinini F, Polatti F, Facchinetti F. Course of primary headaches during hormone replacement therapy. Maturitas 2001; 38:157-63.

    Silberstein SD. Hormone-related headache. M Clin N Am 2001; 85:1017-35.

    Silberstein SD, de Lignieres B. Migraine, menopause and hormonal replacement therapy. Cephalalgia 2000; 20:214-2.

8.4. Головная боль, связанная с отменой препаратов

    Abbott PJ. Caffeine: a toxicological overview. Med J Aust 1986; 145:518-21.

    Baumgartner GR, Rowen RC. Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial. South Med J 1991; 84:312-21.

    Dalessio DJ. (1980). Wolff’s headache and other head pain, Oxford University Press, Oxford. Epstein MT, Hockaday JM, Hockaday TDR. Migraine and reproductive hormones through the menstrual cycle. Lancet 1975; 1:543-8.

    Greden JF, Fontaine M, Lubetsky M, Chamberlin K. Anxiety and depression associated with caffeinism among psychiatric inpatients. Am J Psychiatr 1978; 135:963-6.

    Laska EM, Sunshine A, Mueller F, Elvers WB, Siegel C, Rubin A. Caffeine as an analgesic adjuvant. JAMA 1984; 251:1711-8.

    Lichten E, Lichten J, Whitty A, Pieper D. The confirmation of a biochemical marker for women’s hormonal migraine: the depo-oestradiol challenge test. Headache 1996; 36:367-71.

    Raskin NH, Appenzeller O. Headache, Saunders, Philadelphia. 1980.

    Silverman K, Evans SM, Strain EC, Griffiths RR. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Eng J Med 1992; 327:1109-14.

    Somerville B. Estrogen withdrawal migraine. Neurology 1975; 25:239-50.

    vanDusseldorp M, Katan MB. Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double blind trial. Br Med J 1990; 300:1558-9.

    White BC, Lincoln CA, Pearcz NW, Reeb R, Vaida C. Anxiety and muscle tension as consequence of caffeine withdrawal. Science 1980; 209:1547-8.

9.1.1. Головная боль, связанная с бактериальным менингитом

    Drexler ED. Severe headache: when to worry, what to do Postgrad Med 1990; 87:164-70, 173-80.

    Francke E. The many causes of meningitis. Postgrad Med 1987; 82:175-8, 181-3, 187-8.

    Gedde-Dahl TW, Lettenstrom GS, Bovre K. Coverage for meningococcal disease in the Norwegian morbidity and mortality statistics. NIPH Ann 1980; 3(2):31-5.

    Jones HR, Siekert RG. Neurological manifestation of infective endocarditis. Brain 1989; 112:1295-315.

    Tonjum T, Nilsson F, Bruun JH, Hanebeg B. The early phase of meningococcal disease. NIPH Ann 1983; 6:175-81.

    Zhang SR, Zhang YS, Zhao XD. Tuberculous meningitis with hydrocephalus: a clinical and CT study. Chung Hua Nei Ko Tsa Chih 1989; 28:202-4.

9.1.2. Головная боль, связанная с лимфоцитарным менингитом

    Cochius JI, Burns RJ, Willoughby JO. CNS cryptococcosis: unusual aspects. Clin Exp Neurol 1989; 26:183-91.

    Dalton M, Newton RW. Aseptic meningitis. Dev Med Child Neurol 1991; 33:446-58.

    Gomez-Arada F, Canadillas F, Marti-Masso FJ et al. Pseudomi-graine with temporary neurological symptoms and lym-phocytic pleocytosis. Brain 1997; 120:1105-13.

    Mak SC, Jeng JE, Jong JY, Chiang CH, Chou LC. Clinical observations and virological study of aseptic meningitis in the Kaohsinug area. Taiwan I Hsueh Hui Twa Chih 1990; 89:868-72.

    Pachner AR, Steere AC. Neurological findings of Lyme disease. Yale Biol Med 1984; 57:481-3.

    Pachner  AR, Steere AC. The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radicu-loneuritis. Neurology 1985; 35:47-53.

    Singer JI, Maur PR, Riley JP, Smith PB. Management of central nervous system infections during an epidemic of enterovi-ral aseptic meningitis. J Pediatr 1980; 96:559-63.

9.1.3. Головная боль, связанная с энцефалитом

    Brooks RG, Licitra CM, Peacock MG. Encephalitis caused by Coxiella burnetii. Ann Neurol 1986; 20:91-3.

    Davis LE, McLaren LC. Relapsing herpes simplex encephalitis following antiviral therapy. Ann Neurol 1983; 13:192-5.

    Domachowske JB, Cunningham CK, Cummings DL, Crosley CJ, Hannan WP, Weiner LB. Acute manifestations and neurologic sequelae of Epstein-Barr virus encephalitis in children. Pediatr Infect Dis J 1996; 15:871-5.

    Kennedy PG. Retrospective analsys of 46 cases of simplex encephalitis seen in Glasgow between 1962 and 1985. OJM 1988; 86:533-40.

    Kennedy PG, Adams IH, Graham DI, Clements GB. A clinico-pathological study of herpes simplex encephalitis. Neu-, ropathol Appl Neurobiol 1998; 14:395-415.

    Poneprasert B. Japanese encephalitis in children in, northern Thailand. Southeast Asian J Trop Med Public health 1989; 20:599-603.

    Saged JI, Weinstein Mo, Miller DC. Chronic encephalitis possibly due to herpes simplex virus: two cases. Neurology 1985; 35:1470-2.

9.1.4. Головная боль, связанная с мозговым абсцессом

    Chalstrey S, Pfleiderer AG, Moffat DA. Persisting incidence and mortality of sinogenic cerebral abscess: a continuing reflection of late clinical diagnosis. J R Soc Med 1991; 84:193-5.

    Chun CH, Johnson JD, Hofstetter M, Raff MJ. Brain abscess: a study of 45 consecutive cases. Medicine 1986; 65:415-31.

    Harris LF, Maccubbin DA, Triplett JN, Haws FB. Brain abscess: recent experience at a community hospital. South Med J 1985; 78:704-7.

    Kulay A, Ozatik N, Topucu I. Otogenic intracranial abscesses. Acta Neurochir (Wien) 1990; 107:140-6.

    Yen FT, Chan ST, Huang TS. Brain abscess: with spcial reference to otolaryngologic sources of infection. Otolaryngol Head Neck Surg 1995; 113:15-22.

9.1.5. Головная боль, связанная с субдуральной эмпиемой

    Hodges J, Anslow P, Gillet G. Subdural empyema: continuing diagnostic problems in the CT scan era. QJM 1986; 59:387-93.

    Mclntyre PB, Lavercombe PS, Kemp RJ, McCormack JG. Subdural and epidural empyema: diagnostic and therapeutic problems. Med J Aust 1991; 154:653-7.

    Sellik JA. Epidural abscess and subdural empyema. J Am Osteopath Assoc 1989; 89:806-10.

9.2. Головные боли, свяанные с системными инфекциями

    De Marinis M, Welch KM, Headache associated with non-cephalic infections: classification and mechanisms. Cepha-lalgia 1992; 12:197-201.

9.3. Головная боль, связанная со СПИДом/ВИЧ-инфекцией

    Brew BJ, Miller J. Human immunodeficiency virus-related headache. Neurology 1993; 43:1098-100.

    Denning DW. The neurological features of HIV infection. Biomed Pharmacother 1988; 42:11-4.

    Evers S, Wibbeke B, Reichelt D, Suhr B, Brilla R, Husstedt IW. The impact of HIV infection on primary headache. Unexpected findings from retrospective, cross-sectional, and prospective analyses. Pain 2000; 85:191-200.

    Hollander H, Strimgari S. Human immunodeficiency virus-associated meningitis. Clinical course and correlations. Am J Med 1987; 83:813-6.

    Rinaldi R, Manfred R, Azzimondi G et al. Recurrent ’migrainelike’ episodes in patients with HIV disease. Headache 1007; 37:443-8.

    Weinke T, Rogler G, Sixt C et al. Cryptococcosis in AIDS patients: observations concerning CNS involvement. J Neurol 1989; 236:38-42.

9.4. Хроническая постинфекционная головная боль

    Bohr V, Hansen B, Kjersen H, Rasmussen N, Johnsen N, Kris-tensen HS, Jessen O. Sequelae from bacterial meningitis and their relation to the clinical condition during acute illness, based on 667 questionnaire returns. Part II of a three part series. J Infect 1983; 7:102-10.